通过破坏激活剂-调解剂相互作用来抑制真菌的多药性
Joy L Nishikawa1,2, Andras Boeszoermenyi3, Luis A Vale-Silva4
1Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts 02129, USA.
Nature
|February 18, 2016
概括
研究人员开发了一种小分子抑制剂 (iKIX1),以中介体为向,以对抗耐药性真菌感染. 这种方法使抗真菌药物耐药的Candida glabrata重新敏感,为传染病提供了一种新的治疗策略.
科学领域:
- 分子生物学
- 医学化学
- 菌群学
背景情况:
- 转录激活剂通过调节基因表达的共同激活剂,如中介体.
- 功能失调的转录激活剂与疾病有关,但向疗法受到分子理解的限制.
- 由于Pdr1转录因子的突变,Candida glabrata是一种正在上升的真菌病原体,表现出阿醇抗真菌性.
研究的目的:
- 在Candida glabrata中识别Pdr1- Gal11AKIX域相互作用的小分子抑制剂.
- 探索小分子向介质复合相互作用作为对抗抗药性真菌感染的治疗策略.
主要方法:
- 序列生物化学和体内高通量查以确定抑制剂.
- 用核磁共振 (NMR) 确定Candida glabrata Gal11A KIX域的结构.
- 在体外和动物模型中测试化合物对耐药C. glabrata的疗效.
主要成果:
- 鉴定出一种化合物iKIX1, 抑制了Pdr1-Gal11A KIX域的相互作用.
- 在C. glabrata中,iKIX1有效抑制了Pdr1依赖基因的激活.
- 在体外和体内动物模型中,iKIX1对抗抗菌剂重新敏感化了耐醇的C. glabrata.
- 核磁共振结构阐明了抑制的分子机制.
结论:
- 针对中介体内转录因子结合部位的小分子是真菌传染病的可行治疗策略.
- 在Candida glabrata感染中,iKIX1具有克服醇耐药性的潜力.
- 了解转录激活剂和调解剂的分子相互作用为药物开发提供了新的途径.
相关概念视频
Antifungal Agents
34
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
34
Combined Effects of Drugs: Synergism
7.4K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
7.4K
Eukaryotic Transcription Inhibitors
11.3K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.3K
Drugs that Stabilize Microtubules
2.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Inhibition of CDK Activity
5.6K
5.6K
Inhibition of Cdk Activity
6.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K


